AZD1152 in Patients With Advanced Solid Malignancies
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 127 |
| Updated: | 1/11/2017 |
| Start Date: | May 2006 |
| End Date: | January 2018 |
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
The primary purpose of this protocol is to investigate the safety and tolerability of
AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion
for 2 consecutive days every 14 days in patients with advanced solid malignancies.
AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion
for 2 consecutive days every 14 days in patients with advanced solid malignancies.
Inclusion Criteria:
- Histological or cytological confirmation of a solid, malignant tumour
- At least one measurable or non-measurable site of disease as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) criteria.
Exclusion Criteria:
- Participation in an investigational drug study within the 21 days prior to therapy or
those who have not recovered from the effects of an investigational study drug
- Recent major surgery within 4 weeks prior to entry into the study
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials